AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £657.13m
- £679.98m
- £55.20m
REG - Allergy Therapeutics - Prelim Results and publication of Annual Report
AnnouncementREG - Allergy Therapeutics - Primary Safety Endpoint Met in PROTECT trial
AnnouncementREG - Allergy Therapeutics - Company to Evaluate Dual Listing on HKEX
AnnouncementREG - AIM - AIM Notice - 30/10/2025
AnnouncementREG - Allergy Therapeutics - G308 Phase III Year 2 Patient Screening Starts
AnnouncementREG - Allergy Therapeutics - Warrant Exercise and Paydown of Debt
AnnouncementREG - Allergy Therapeutics - Further progress in Phase I/IIa PROTECT trial
AnnouncementRCS - Allergy Therapeutics - Grass MATA MPL Publications in Allergy Journal
AnnouncementREG - Allergy Therapeutics - Trading update for the year ended 30 June 2025
AnnouncementREG - Allergy Therapeutics - PDMR Dealings
AnnouncementRCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI
AnnouncementRCS - Allergy Therapeutics - EAACI Early Career Research Award
AnnouncementREG - Allergy Therapeutics - Interim Results for six months ended 31 Dec 2024
AnnouncementREG - Allergy Therapeutics - Advancement to final phase of PROTECT trial
AnnouncementREG - Allergy Therapeutics - New Executive Long Term Incentive Awards
AnnouncementRCS - Allergy Therapeutics - Presentations at 2025 AAAAI / WAO Joint Congress
AnnouncementREG - Allergy Therapeutics - Grass MATA MPL Phase III data published in Allergy
AnnouncementREG - Allergy Therapeutics - Grant of Options
AnnouncementREG - Allergy Therapeutics - Half Year Trading update
Announcement